Redhill Boipharma Ltd (RDHL)       0.8416  -0.03 (-3.26%)

0.8416  -0.03 (-3.26%)

US7574681034 - ADR - After market: 0.84 0 (-0.19%)

News Image
6 days ago - Chartmill

Which stocks have an unusual volume on Tuesday?

Let's have a look at what is happening on the US markets on Tuesday. Below you can find the stocks with an unusual volume in today's session.

News Image
7 days ago - Chartmill

These stocks have an unusual volume in today's session

Let's have a look at what is happening on the US markets on Monday. Below you can find the stocks with an unusual volume in today's session.

News Image
11 days ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

It's time for the last breakdown of the biggest pre-market stock movers of the week and we look at what's happening Friday morning!

News Image
12 days ago - RedHill Biopharma Ltd.

RedHill Biopharma Announces Q1/22 Highlights: On Track for Positive Cash from Operations in H2/22

Targeting positive cash from operations to start during H2/22[1] Focus on earlier achievement of operational profitability thanks to a recently implemented...

News Image
18 days ago - RedHill Biopharma Ltd.

RedHill Biopharma to Host First Quarter 2022 Financial Results and Operational Highlights Webcast on June 23, 2022

/PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will report...

News Image
a month ago - RedHill Biopharma Ltd.

RedHill Presents New Talicia® Data Analyses at DDW 2022

Talicia's efficacy and safety profile evaluated in patients with H. pylori infection and diabetes mellitus, a large and challenging patient population...

News Image
2 months ago - RedHill Biopharma Ltd.

RedHill Biopharma Announces $15 Million Registered Direct Offering with a Leading Healthcare Investor

/PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered...

News Image
3 months ago - RedHill Biopharma Ltd

RedHill Biopharma Ltd Announces Potent Omicron Inhibition with RedHill's Opaganib

Oral opaganib's reported potent in vitro activity against Omicron adds to previously observed inhibition of Delta and other SARS-CoV-2 variants of concern that cause COVID-19; Testing conducted by The University of Hong Kong School of Public Health, a world renowned WHO collaborating center Based on the new and previously announced data, opaganib's unique human host-targeted, dual antiviral and anti-inflammatory suggested mechanism is expected

News Image
5 months ago - RedHill Biopharma Ltd.

RedHill Biopharma's Oral Opaganib Reduces Mortality by 70% Given on Top of Remdesivir and Corticosteroids in Severe COVID-19

/PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced results from two...